Relation of stem cell markers ALDH1 and CD44 with clinicopathological factors in urothelial carcinomas of urinary bladder
Yazarlar (10)
Serkan Senol
Istanbul Medeniyet University, Türkiye
Asif Yildirim
Istanbul Goztepe Training & Research Hospital, Türkiye
Ibrahim Akalin
Istanbul Medeniyet University, Türkiye
Fatih Uruc
Fatih Sultan Mehmet Training & Research Hospital, Türkiye
Bengu Cobanoglu
Istanbul Medeniyet University, Türkiye
Sarenur Yilmaz
Istanbul Medeniyet University, Türkiye
Bahar Ceyran
Istanbul Medeniyet University, Türkiye
Duygu Kosemetin
Istanbul Medeniyet University, Türkiye
Dilek Ece
Istanbul Kartal Dr Lutfi Kirdar Training & Research Hospital, Türkiye
Prof. Dr. Abdullah AYDIN
Kırşehir Ahi Evran Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (ESCI dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE | ||
| Dergi ISSN | 1940-5901 Wos Dergi Scopus Dergi | ||
| Makale Dili | İngilizce | Basım Tarihi | 01-2015 |
| Cilt / Sayı / Sayfa | 8 / 3 / 4195–4203 | DOI | – |
| Özet |
| Molecular studies are ongoing in regards to superficial urothelial carcinoma of the bladder (UCB) either to define targeted therapy or to better select aggressive therapy candidates and also to delineate the outcome of the disease. In this study, we aimed to present the impact of ALDH1 and CD44 as stem cell markers in tumorigenesis and their prognostic value in urothelial carcinoma. We investigated ALDH1 and CD44 immunohistochemically in paraffin-embedded material of 125 non-muscle-invasive (NMI) cases in 163 UCB patients. In the NMI-UCB subgroup, we found ALDH1 to be significantly correlated with all poor prognostic factors, including high stage (≥pT2), high grade, recurrence and progression development and poor survey (P=0.001) in contrast to CD44 expression (P>0.05). Although ALDH1 expression had a good correlation with a poor clinical course of UCB, it could be used as a molecular marker to determine the best treatment strategy and could contribute to the development of targeted therapies. |
| Anahtar Kelimeler |
| ALDH1 | CD44 | bladder carcinoma | prognostic value |
